Nanowear is a connected-self technology platform for diagnostics and chronic disease management. Utilizing proprietary, FDA 510(k) cleared, cloth-based nanosensors, Nanowear’s flagship product, SimpleSense, is transforming Congestive Heart Failure (CHF) management. The non-invasive SimpleSense undergarment simultaneously captures ECG, Heart Rate Variability, Respiratory Rate, Impedance Cardiography (Stroke volume/cardiac output), Thoracic Impedance, Cardio-phonography (“S3”) and actigraphy. Worn by patients following discharge of a CHF-related hospitalization event, SimpleSense transmits these 7 parameters to a cloud-based environment via an iOS mobile application and physician dashboard. Data aggregation and algorithmic analysis alerts medical professionals of irregular movement from relative baseline metrics ultimately identifying decompensating Heart Failure in advance of a hospitalizing event, enabling medical professionals to manage their patients remotely. Nanowear’s first FDA 510(k) clearance of SimplECG already proven ability to capture and transmit medical-grade ECG, Heart Rate and respiratory rate.
The ability to remotely monitor CHF patients and keep them out of the hospital is essential in today’s world of outcomes-based medicine. Not only does CHF account for a large and growing population of the chronically ill, ~700K new U.S. cases annually, it’s also a systemic financial burden on providers with a 25% rate of recidivism within 30 days of discharge — a risk that now falls on providers with CMS care requirements and penalties both increasing.
The goal of SimpleSense will be to improve patient outcomes and reduce recidivism, following discharge, through the ability to promote real-time medication titration, coordinate care plan modifications, and potentially schedule outpatient visits.